Aura Biosciences, Inc. Common Stock (AURA) is a publicly traded Healthcare sector company. As of September 1, 2026, AURA trades at $7.44 with a market cap of $744.60M and a P/E ratio of -4.25. AURA moved +3.55% today. Year to date, AURA is +40.19%; over the trailing twelve months it is +17.75%. Its 52-week range spans $4.35 to $9.54. Analyst consensus is strong buy with an average price target of $20.50. Rallies surfaces AURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AURA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AURA recently traded at $7.44. Market cap is $744.60M. P/E ratio is -4.25. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $7.44 |
| Market Cap | $744.60M |
| P/E Ratio | -4.25 |
| EPS | $-1.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.54 |
| 52-Week Low | $4.35 |
| Volume | 425.67K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-106.19M |
| Gross Margin | 0.00% |
3 analysts cover AURA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.50.